ECSP088104A - Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso - Google Patents
Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su usoInfo
- Publication number
- ECSP088104A ECSP088104A EC2008008104A ECSP088104A ECSP088104A EC SP088104 A ECSP088104 A EC SP088104A EC 2008008104 A EC2008008104 A EC 2008008104A EC SP088104 A ECSP088104 A EC SP088104A EC SP088104 A ECSP088104 A EC SP088104A
- Authority
- EC
- Ecuador
- Prior art keywords
- disorder
- syndrome
- pain
- highly selective
- fibromyalgia
- Prior art date
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 3
- 230000009977 dual effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940076279 serotonin Drugs 0.000 title abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003497 Asphyxia Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 abstract 1
- 208000003782 Raynaud disease Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000030963 borderline personality disease Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 201000006145 cocaine dependence Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000001457 vasomotor Effects 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan inhibidores de la retoma de norepinefrina y serotonina duales altamente selectivos. Estos compuestos tienen un perfil de efecto colateral bajo y son útiles en composiciones y productos para uso en el tratamiento de una variedad de afecciones que incluyen depresión, fibromialgia, ansiedad, trastorno de pánico, agorafobia, trastorno de estrés post traumático, trastorno disfórico premenstrual, trastorno de déficit de atención, trastorno obsesivo compulsivo, trastorno de ansiedad social, trastorno de ansiedad generalizada, autismo, esquizofrenia, obesidad, anorexia nerviosa, bulimia nerviosa, Síndrome de Gilles de la Tourette, sofoco vasomotriz, adicción a la cocaína y al alcohol, disfunción sexual, trastorno límite de la personalidad, síndrome de fibromialgia, dolor neuropático diabético, síndrome de fatiga crónica, dolor, dolor visceral, síndrome Shi Drager, síndrome de Raynaud, enfermedad de Parkinson, y epilepsia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69966505P | 2005-07-15 | 2005-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088104A true ECSP088104A (es) | 2008-04-28 |
Family
ID=37453209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008104A ECSP088104A (es) | 2005-07-15 | 2008-01-14 | Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070015828A1 (es) |
| EP (1) | EP1904434A2 (es) |
| JP (1) | JP2009501229A (es) |
| KR (1) | KR20080034921A (es) |
| CN (1) | CN101223129A (es) |
| AR (1) | AR057662A1 (es) |
| AU (1) | AU2006270380A1 (es) |
| BR (1) | BRPI0613031A2 (es) |
| CA (1) | CA2615362A1 (es) |
| CR (1) | CR9661A (es) |
| EC (1) | ECSP088104A (es) |
| GT (1) | GT200600308A (es) |
| IL (1) | IL188614A0 (es) |
| MX (1) | MX2008000680A (es) |
| NO (1) | NO20080006L (es) |
| PE (1) | PE20070247A1 (es) |
| RU (1) | RU2007149183A (es) |
| TW (1) | TW200740724A (es) |
| WO (1) | WO2007011594A2 (es) |
| ZA (1) | ZA200800408B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| WO2007067501A1 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| EP1934167A2 (en) | 2006-07-26 | 2008-06-25 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of o-desmethylvenlafaxine |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| KR101343027B1 (ko) | 2007-11-26 | 2013-12-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | Ｏ-데스메틸벤라팍신 푸마레이트의 결정형 |
| US9339500B2 (en) * | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
| US20100016638A1 (en) * | 2008-07-21 | 2010-01-21 | Zdenko Hamersak | Method for preparation of o-desmethylvenlafaxine using polythiolates |
| CA2779711C (en) * | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| WO2011121452A2 (en) | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| DE60221642T3 (de) * | 2001-02-12 | 2017-10-26 | Wyeth LLC (n.d.Ges.d. Staates Delaware) | O-desmethyl-venlafaxine succinat salz |
| WO2005077340A1 (en) * | 2004-02-06 | 2005-08-25 | Wyeth | Multiparticulate o-desmethylvenlafaxine salts and uses thereof |
| CN101151026A (zh) * | 2005-03-31 | 2008-03-26 | 惠氏公司 | O-去甲文拉法辛和巴泽昔芬联合产品及其应用 |
-
2006
- 2006-07-13 AR ARP060103013A patent/AR057662A1/es unknown
- 2006-07-13 EP EP06786969A patent/EP1904434A2/en not_active Withdrawn
- 2006-07-13 WO PCT/US2006/026991 patent/WO2007011594A2/en not_active Ceased
- 2006-07-13 TW TW095125667A patent/TW200740724A/zh unknown
- 2006-07-13 PE PE2006000834A patent/PE20070247A1/es not_active Application Discontinuation
- 2006-07-13 CN CNA2006800258619A patent/CN101223129A/zh active Pending
- 2006-07-13 CA CA002615362A patent/CA2615362A1/en not_active Abandoned
- 2006-07-13 BR BRPI0613031-3A patent/BRPI0613031A2/pt not_active IP Right Cessation
- 2006-07-13 MX MX2008000680A patent/MX2008000680A/es unknown
- 2006-07-13 AU AU2006270380A patent/AU2006270380A1/en not_active Abandoned
- 2006-07-13 RU RU2007149183/04A patent/RU2007149183A/ru not_active Application Discontinuation
- 2006-07-13 KR KR1020087003405A patent/KR20080034921A/ko not_active Withdrawn
- 2006-07-13 JP JP2008521551A patent/JP2009501229A/ja not_active Withdrawn
- 2006-07-13 US US11/485,663 patent/US20070015828A1/en not_active Abandoned
- 2006-07-19 GT GT200600308A patent/GT200600308A/es unknown
-
2007
- 2007-01-15 CR CR9661A patent/CR9661A/es not_active Application Discontinuation
-
2008
- 2008-01-02 NO NO20080006A patent/NO20080006L/no not_active Application Discontinuation
- 2008-01-06 IL IL188614A patent/IL188614A0/en unknown
- 2008-01-14 ZA ZA200800408A patent/ZA200800408B/xx unknown
- 2008-01-14 EC EC2008008104A patent/ECSP088104A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070015828A1 (en) | 2007-01-18 |
| WO2007011594A2 (en) | 2007-01-25 |
| CN101223129A (zh) | 2008-07-16 |
| WO2007011594A3 (en) | 2007-04-26 |
| MX2008000680A (es) | 2008-03-14 |
| BRPI0613031A2 (pt) | 2012-01-03 |
| PE20070247A1 (es) | 2007-04-11 |
| EP1904434A2 (en) | 2008-04-02 |
| TW200740724A (en) | 2007-11-01 |
| KR20080034921A (ko) | 2008-04-22 |
| JP2009501229A (ja) | 2009-01-15 |
| NO20080006L (no) | 2008-02-01 |
| CR9661A (es) | 2008-03-07 |
| ZA200800408B (en) | 2008-12-31 |
| IL188614A0 (en) | 2008-04-13 |
| AU2006270380A1 (en) | 2007-01-25 |
| AR057662A1 (es) | 2007-12-12 |
| GT200600308A (es) | 2007-04-10 |
| RU2007149183A (ru) | 2009-08-20 |
| CA2615362A1 (en) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088104A (es) | Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso | |
| BRPI0714558B8 (pt) | processo para a preparação de (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol | |
| DE602007004494D1 (de) | Herstellung von (2r,3r)-3-(3-methoxyphenyl)-n,n,2- trimethylpentanamin | |
| BR0314429A (pt) | Derivados de aza-heterociclil-metil antidepressivo e benzodioxanos fundidos por heterociclo | |
| PA8781801A1 (es) | Derivados heteroarilo antidepresivos de benzodioxanos heterociclo-fusionados | |
| BR112014008401A2 (pt) | processo para a preparação de metoxi melonal | |
| ATE522475T1 (de) | Verfahren zur herstellung eines heteroatom enthaltenden silikates | |
| DE502004001542D1 (de) | Verfahren zur herstellung von ionischen flüssigkeiten mit alkylsulfat und funktionalisierten alkylsulfat-anionen | |
| ATE544516T1 (de) | Verfahren zur herstellung von gesättigten ethern durch hydrierung ungesättigter ether | |
| DE50311475D1 (de) | Verfahren zur herstellung von primären aminen durch hydrierung von nitrilen | |
| CL2012000533A1 (es) | Compuesto derivado de tiazol o una de sus sales, para el tratamiento y/o profilaxis de un trastorno de ansiedad seleccionado de trastorno de panico, agorafobia, trastorno obsesivo compulsivo, fobia social, trastorno de estres post-traumatico, fobia particular, entre otros. | |
| ATE409030T1 (de) | Sphingolipiden zur verbesserung der darmflorazusammensetzung | |
| AR059227A1 (es) | Proceso para la preparacion de compuestos organicos | |
| WO2002088136A3 (en) | Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene | |
| ECSP099045A (es) | Sal xinafoato de un compuesto de 5-oxazol-2-il-quinolina sustituido | |
| IL185467A0 (en) | Crystalline forms of (1rs,3rs,6rs)-6-dimethylaminomethyl-1-(3-methoxy-phenyl) cyclohexane-1,3-diol hydrochloride | |
| ATE506342T1 (de) | Ein verfahren zur herstellung von tolterodin | |
| BR0314430A (pt) | Derivados de cicloalquilamina antidepressiva dos benzodioxanos fundidos por heterociclo | |
| CR7726A (es) | Antidepresivos derivados de indoalquilo de benzodioxan metilaminas de heterociclo fusionado | |
| JP2011519917A5 (es) | ||
| ATE517086T1 (de) | Verfahren zur synthese von 3-amino-1- arylpropylindolen | |
| ATE529396T1 (de) | Verfahren zur herstellung von iohexol | |
| BR0314280A (pt) | Composto; método de tratamento de um indivìduo acometido por uma condição de depressão, ansiedade, distúrbios do pânico, de tensão pós-traumática, disfórico pré-menstrual, de deficiência da atenção, obsessivos-compulsivos e alimentares, obesidade, rubor vasomotor, dependência de álcool e cocaìna e disfunção sexual; composição farmacêutica e uso do mesmo | |
| WO2008013993A3 (en) | Processes for the synthesis of o-desmethylvenlafaxine | |
| IL207706A0 (en) | Method for the production of (1rs,3rs,6rs)-6-dimethyl amino ethyl-1-(3-methoxy phenyl)-cyclohexane-1,3-diol |